KR102892275B1 - 이미다조피리디닐 화합물 및 신경퇴행성 장애의 치료를 위한 그의 용도 - Google Patents

이미다조피리디닐 화합물 및 신경퇴행성 장애의 치료를 위한 그의 용도

Info

Publication number
KR102892275B1
KR102892275B1 KR1020217030103A KR20217030103A KR102892275B1 KR 102892275 B1 KR102892275 B1 KR 102892275B1 KR 1020217030103 A KR1020217030103 A KR 1020217030103A KR 20217030103 A KR20217030103 A KR 20217030103A KR 102892275 B1 KR102892275 B1 KR 102892275B1
Authority
KR
South Korea
Prior art keywords
fluoro
pyridin
imidazo
carboxamide
methylphenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217030103A
Other languages
English (en)
Korean (ko)
Other versions
KR20210122862A (ko
Inventor
이진화
조수연
임건승
박아영
김재은
김미순
임성묵
Original Assignee
주식회사 퍼스트바이오테라퓨틱스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 퍼스트바이오테라퓨틱스 filed Critical 주식회사 퍼스트바이오테라퓨틱스
Publication of KR20210122862A publication Critical patent/KR20210122862A/ko
Application granted granted Critical
Publication of KR102892275B1 publication Critical patent/KR102892275B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
KR1020217030103A 2019-02-22 2020-02-21 이미다조피리디닐 화합물 및 신경퇴행성 장애의 치료를 위한 그의 용도 Active KR102892275B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962809230P 2019-02-22 2019-02-22
US62/809,230 2019-02-22
PCT/IB2020/051469 WO2020170205A1 (en) 2019-02-22 2020-02-21 Imidazopyridinyl compounds and use thereof for treatment of neurodegenerative disorders

Publications (2)

Publication Number Publication Date
KR20210122862A KR20210122862A (ko) 2021-10-12
KR102892275B1 true KR102892275B1 (ko) 2025-11-27

Family

ID=72141573

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020217030103A Active KR102892275B1 (ko) 2019-02-22 2020-02-21 이미다조피리디닐 화합물 및 신경퇴행성 장애의 치료를 위한 그의 용도
KR1020217030099A Withdrawn KR20210122861A (ko) 2019-02-22 2020-02-21 이미다조피리디닐 화합물 및 증식성 질환의 치료를 위한 그의 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020217030099A Withdrawn KR20210122861A (ko) 2019-02-22 2020-02-21 이미다조피리디닐 화합물 및 증식성 질환의 치료를 위한 그의 용도

Country Status (10)

Country Link
US (4) US20220242861A1 (https=)
EP (2) EP3927706A4 (https=)
JP (2) JP7609790B2 (https=)
KR (2) KR102892275B1 (https=)
CN (2) CN113454081B (https=)
AU (1) AU2020224401A1 (https=)
CA (1) CA3131059A1 (https=)
IL (1) IL285708B2 (https=)
MX (1) MX2021010122A (https=)
WO (2) WO2020170205A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020224401A1 (en) 2019-02-22 2021-10-14 1ST Biotherapeutics, Inc. Imidazopyridinyl compounds and use thereof for treatment of neurodegenerative disorders
CN115968362B (zh) * 2020-08-21 2025-06-13 第一生物治疗股份有限公司 作为pet放射性示踪剂的[18f]-标记的咪唑并吡啶衍生物
US12398156B2 (en) 2020-08-21 2025-08-26 1ST Biotherapeutics, Inc. Compounds for prevention or treatment of neurodegenerative disorders
WO2022064459A1 (en) * 2020-09-28 2022-03-31 1ST Biotherapeutics, Inc. Indazoles as hematopoietic progenitor kinase 1 (hpk1) inhibitors and methods of using same
EP4236950A4 (en) * 2020-10-29 2024-10-23 Merck Sharp & Dohme LLC N-LINKED ISOQUINOLINE AMIDES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
WO2022165529A1 (en) * 2021-02-01 2022-08-04 Janssen Biotech, Inc. Small molecule inhibitors of salt inducible kinases
CN115724839A (zh) * 2021-08-26 2023-03-03 科辉智药生物科技(深圳)有限公司 Sarm1酶活性抑制剂及其应用
EP4499643A4 (en) * 2022-03-25 2026-01-28 1St Biotherapeutics Inc INDAZOLES USED AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) INHIBITORS AND THEIR METHODS OF USE
CN116354959B (zh) * 2023-03-10 2024-04-19 石河子大学 一种N-N桥连噻唑单元的β-咔啉衍生物及其制备方法、应用
CN121941688A (zh) * 2023-10-09 2026-04-28 浙江海正药业股份有限公司 多取代芳基类衍生物及其制备方法和用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015134171A1 (en) * 2014-03-06 2015-09-11 Takeda Pharmaceutical Company Limited Heteroarylamide inhibitors of tbk1

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020084116A (ko) 2000-02-07 2002-11-04 애보트 게엠베하 운트 콤파니 카게 2-벤조티아졸릴 우레아 유도체 및 이의 단백질 키나제억제제로서의 용도
CN101384586A (zh) * 2006-02-14 2009-03-11 诺华公司 Pi-3激酶抑制剂及其应用方法
PE20070978A1 (es) * 2006-02-14 2007-11-15 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
EP2058309A4 (en) 2006-08-04 2010-12-22 Takeda Pharmaceutical CONDENSED HETEROCYCLIC COMPOUND
CA2693232A1 (en) 2007-07-18 2009-01-22 Novartis Ag Bicyclic heteroaryl compounds and their use as kinase inhibitors
TW200911798A (en) 2007-08-02 2009-03-16 Amgen Inc PI3 kinase modulators and methods of use
ES2400604T3 (es) * 2007-08-17 2013-04-11 Icagen, Inc. Heterociclos como moduladores del canal de potasio
AU2008343813B2 (en) * 2007-12-19 2012-04-12 Amgen Inc. Inhibitors of PI3 kinase
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
AR071523A1 (es) 2008-04-30 2010-06-23 Merck Serono Sa Compuestos biciclicos fusionados, un proceso para su preparacion, el compuesto para ser utilizado como medicamento en el tratamiento y profilaxis de enfermedades, una composicion farmaceutica y un conjunto que comprende paquetes separados del compuesto y de un ingrediente activo del medicamento
WO2010008847A2 (en) 2008-06-24 2010-01-21 Takeda Pharmaceutical Company Limited Pi3k/m tor inhibitors
BRPI0915231A2 (pt) 2008-07-08 2018-06-12 Intellikine Inc compostos inibidores de quinase e métodos de uso
WO2010100144A1 (en) 2009-03-04 2010-09-10 Merck Serono S.A. Fused bicyclic compounds as inhibitors for pi3 kinase
US8765747B2 (en) * 2009-06-12 2014-07-01 Dana-Farber Cancer Institute, Inc. Fused 2-aminothiazole compounds
NZ598220A (en) * 2009-08-17 2014-02-28 Intellikine Llc Heterocyclic compounds and uses thereof
EA026115B1 (ru) * 2010-12-17 2017-03-31 Ф. Хоффманн-Ля Рош Аг Замещенные 6,6-конденсированные азотсодержащие гетероциклические соединения и их применение
WO2014004863A2 (en) * 2012-06-27 2014-01-03 Alzheimer's Institute Of America, Inc. Compounds, compositions, and therapeutic uses thereof
EP2892534B8 (en) 2012-09-06 2021-09-15 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
MX365640B (es) 2012-12-21 2019-06-10 Plexxikon Inc Compuestos y metodos para la modulacion de quinasas y sus indicaciones.
WO2018017435A1 (en) * 2016-07-22 2018-01-25 Accro Bioscience Inc. Heteroaryl compounds as inhibitors of necrosis, composition and application thereof
WO2018237370A1 (en) * 2017-06-23 2018-12-27 Accro Bioscience Inc. Heteroaryl compounds as inhibitors of necrosis, composition and method using the same
AU2018346051B2 (en) 2017-10-02 2022-11-10 1st Biotherapeutics Inc. Benzothiazol compounds and methods using the same for treating neurodegenerative disorders
EP3877371A4 (en) * 2018-11-07 2022-07-27 Dana-Farber Cancer Institute, Inc. IMIDAZOPYRIDINE DERIVATIVES AND AZA-IMIDAZOPYRIDINE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF
AU2020224401A1 (en) * 2019-02-22 2021-10-14 1ST Biotherapeutics, Inc. Imidazopyridinyl compounds and use thereof for treatment of neurodegenerative disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015134171A1 (en) * 2014-03-06 2015-09-11 Takeda Pharmaceutical Company Limited Heteroarylamide inhibitors of tbk1

Also Published As

Publication number Publication date
US20210347774A1 (en) 2021-11-11
WO2020170205A1 (en) 2020-08-27
MX2021010122A (es) 2021-09-23
IL285708A (en) 2021-10-31
CN113454081A (zh) 2021-09-28
CN113454082A (zh) 2021-09-28
IL285708B2 (en) 2025-02-01
US20200270246A1 (en) 2020-08-27
AU2020224401A1 (en) 2021-10-14
US11098044B2 (en) 2021-08-24
EP3927706A4 (en) 2022-12-14
JP7609790B2 (ja) 2025-01-07
US12534461B2 (en) 2026-01-27
CA3131059A1 (en) 2020-08-27
KR20210122862A (ko) 2021-10-12
CN113454082B (zh) 2024-07-02
US11802126B2 (en) 2023-10-31
EP3927705A1 (en) 2021-12-29
KR20210122861A (ko) 2021-10-12
US20220242861A1 (en) 2022-08-04
JP2022521536A (ja) 2022-04-08
JP2022521537A (ja) 2022-04-08
CN113454081B (zh) 2024-08-09
US20230365557A1 (en) 2023-11-16
WO2020170206A1 (en) 2020-08-27
IL285708B1 (en) 2024-10-01
EP3927706A1 (en) 2021-12-29
EP3927705A4 (en) 2022-12-07

Similar Documents

Publication Publication Date Title
KR102892275B1 (ko) 이미다조피리디닐 화합물 및 신경퇴행성 장애의 치료를 위한 그의 용도
KR102682398B1 (ko) 다이아실글리세롤 키나아제 저해제로서 헤테로사이클 화합물 및 이의 용도
KR20230067669A (ko) 2-아미노-3-카르보닐 이미다조피리딘 및 피라졸로피리딘 화합물
WO2017187324A1 (en) Substituted fused pyrimidinone compounds
CN121866255A (zh) 毒蕈碱型乙酰胆碱受体m4的正向调节剂
RU2833052C2 (ru) Имидазопиридинильные соединения и их применение для лечения нейродегенеративных расстройств
HK40058868A (en) Imidazopyridinyl compounds and use thereof for treatment of neurodegenerative disorders
HK40058868B (zh) 咪唑并吡啶基化合物及其用於治疗神经退行性疾病的用途
EP4200299B1 (en) Compounds for prevention or treatment of neurodegenerative disorders
CN116457355B (zh) 2-氨基-3-羰基咪唑并吡啶和吡唑并吡啶化合物
HK40096261A (zh) 2-氨基-3-羰基咪唑幷吡啶和吡唑幷吡啶化合物
HK40058867A (en) Imidazopyridinyl compounds and use thereof for treatment of proliferative disorders
HK40058867B (zh) 咪唑幷吡啶基化合物及其用於治疗增生性疾病的用途
HK40022715A (en) Benzothiazol compounds and methods using the same for treating neurodegenerative disorders

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)